HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults

    Bristol-Myers Squibb announced today that the European Commission has approved Evotaz (atazanavir 300mg and cobicistat 150mg) tablets in combination with other antiretroviral agents for the treatment of adults with HIV-1 without known mutations associated with resistance to atazanavir.

    20 July 2015 | BMS press release
  • Scripps Research Institute-Designed Drug Candidate Significantly Reduces HIV Reactivation Rate

    HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the virus and clinical progression to AIDS. But now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have shown that, unlike other antiretroviral therapies, a natural compound called Cortistatin A reduces residual levels of virus from these infected dormant cells, establishing a near-permanent state of latency and greatly diminishing the virus’ capacity for reactivation.

    11 July 2015 | Scripps Research Institute
  • Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide

    Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.

    02 July 2015 | Gilead press release
  • South Korea mulls combining HIV drugs with antivirals to combat MERS

    As the death toll from MERS in South Korea edged to two dozen scientists there say the outbreak is different from in Saudi Arabia and also from its the related virus SARS.

    22 June 2015 | in-Pharma Technologist
  • START Making Sense

    The story of the START trial will continue to be told for a long time to come. For some it will be a tale of rigorous perseverance in the face of strong counter-prevailing headwinds and ultimate arrival at a result that is solid and conclusive. Others will see a single-minded and aggressive defense of a trial by investigators who refused to accept not only the obvious but also the evidence that rendered their design obsolete and even unethical.

    19 June 2015 | North Carolina AIDS Training and Education Center
  • When to START has never been clearer

    Posirtive Lite editor Bob Leahy in conversation with CATIE’s Sean Hosein about START, the important and ground-breaking study that recently provided definitive evidence of the health benefits of starting HIV treatment sooner rather than later.

    10 June 2015 | Positive Lite
  • ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV

    ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment of HIV. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States. Upon receiving Tentative Approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014.

    26 May 2015 | ViiV Healthcare
  • Six questions about HIV/AIDS that deserve more attention

    As HIV investigators work to control and eradicate the virus worldwide, certain myths or misconceptions about the disease have been embraced, whereas other concepts with merit have been left relatively unexplored, argues American HIV/AIDS researcher Jay Levy, M.D., in a Trends in Molecular Medicine commentary. He calls on fellow researchers to continue questioning and not to lose sight of alternative strategies that could ultimately lead to a sustainable, long-term solution to HIV infection.

    15 April 2015 | Eurekalert Inf Dis
  • 'This is what it's really like to live with HIV'

    The number of young men being diagnosed with HIV has doubled in ten years; the number of new diagnoses among gay and bisexual men has reached a record high, according to the most recent data. The virus is rarely out of the news, and yet, because of continuing developments in treatment, few of us understand what life with the condition is like now. Three young men, all diagnosed in their 20s, talk about living with the virus.

    10 April 2015 | Daily Telegraph
  • Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 >500 cells/mm3

    The TEMPRANO study presented as a late breaker oral presentation, included important information for timing of TB prophylaxis and the timing of ART in TB-endemic countries. The conclusions though do not support universally starting treatment at CD4 counts >500 or answer the primary question of the international START study.

    03 March 2015 | HIV i-Base
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.